Mineralys insider plans sale of 14,056 shares

Mineralys Therapeutics, Inc. insider David Rodman filed a Form 144 indicating an intent to sell up to 14,056 shares of common stock through Merrill Lynch on or after 08/13/2026, with an aggregate market value of $372,187.00.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. insider David Rodman filed a Form 144 indicating an intent to sell up to 14,056 shares of common stock through Merrill Lynch on or after 08/13/2026, with an aggregate market value of $372,187.00. The shares relate to the exercise of employee stock options, including 7,707 shares via a broker-assisted cashless exercise dated 08/13/2026 and 6,349 shares for cash dated 08/12/2025. The filing also lists multiple common stock sales in the preceding three months, such as 14,056 shares on 05/13/2026 for $401,789.92 and 9,890 shares on 06/15/2026 for $235,487.24.

Key Figures

Shares in planned sale: 14,056 shares Aggregate market value of planned sale: $372,187.00 Option exercise shares (cashless): 7,707 shares +4 more

7 metrics

Shares in planned sale 14,056 shares Common stock potentially to be sold through Merrill Lynch on or after 08/13/2026

Aggregate market value of planned sale $372,187.00 Market value associated with 14,056 shares of common stock

Option exercise shares (cashless) 7,707 shares Exercise of employee stock options on 08/13/2026, broker assisted with cashless exercise

Option exercise shares (cash) 6,349 shares Exercise of employee stock options on 08/12/2025 for cash

Sale on 05/13/2026 14,056 shares for $401,789.92 Common stock sold by David Rodman on 05/13/2026

Sale on 06/15/2026 9,890 shares for $235,487.24 Common stock sold by David Rodman on 06/15/2026

Recent sale on 08/10/2026 2,170 shares for $58,785.30 Common stock sold by David Rodman on 08/10/2026

Key Terms

Form 144, broker assisted with cashless exercise, Exercise of employee stock options, aggregate market value

4 terms

Form 144 regulatory

"Mineralys insider David Rodman filed a Form 144 indicating an intent to sell shares"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

broker assisted with cashless exercise financial

"08/13/2026 | Broker assisted with cashless exercise Common Stock"

Exercise of employee stock options financial

"08/13/2026 | Exercise of employee stock options | Mineralys Therapeutics, Inc."

aggregate market value financial

"14,056 shares, with an aggregate market value of $372,187.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing by Mineralys Therapeutics (MLYS) insider disclose?

The filing shows that David Rodman may sell up to 14,056 shares of Mineralys Therapeutics common stock through Merrill Lynch on or after 08/13/2026, following exercises of employee stock options.

How many Mineralys Therapeutics (MLYS) shares are covered by this planned Form 144 sale?

The Form 144 covers a potential sale of 14,056 shares of Mineralys Therapeutics common stock, with an indicated aggregate market value of $372,187.00 as referenced in the filing.

What is the source of the Mineralys Therapeutics (MLYS) shares in David Rodman’s Form 144?

The shares relate to the exercise of employee stock options, including 7,707 shares via a broker-assisted cashless exercise on 08/13/2026 and 6,349 shares acquired for cash on 08/12/2025.

Which broker is handling the potential Form 144 stock sale for Mineralys Therapeutics (MLYS)?

The filing lists Merrill Lynch, located at 225 Liberty St, Floor 37, New York, NY 10281, as the broker for the planned sale of 14,056 shares of Mineralys Therapeutics common stock.

What recent Mineralys Therapeutics (MLYS) stock sales by David Rodman are disclosed in the Form 144?

The filing lists multiple past three-month sales, including 14,056 shares on 05/13/2026 for $401,789.92 and 9,890 shares on 06/15/2026 for $235,487.24, along with several smaller transactions.

On which market is Mineralys Therapeutics (MLYS) common stock listed according to the Form 144?

The Form 144 identifies the trading market as NASDAQ for Mineralys Therapeutics common stock associated with the potential sale of 14,056 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 04:13 PM Accepted by SEC EDGAR 08/13/2026 - 04:12 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001672659
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Rodman David Malcom
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	14056	372187.00	82498101	08/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/13/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			7707	08/13/2026	Broker assisted with cashless exercise
Common Stock	08/12/2025	Exercise of employee stock options	Mineralys Therapeutics, Inc.			6349	08/12/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/12/2026	6348	186348.35
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/13/2026	14056	401789.92
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/18/2026	417	11488.35
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/10/2026	2170	54250.00
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/12/2026	6349	151901.37
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/15/2026	9890	235487.24
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/17/2026	4584	114600.00
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/09/2026	2171	65781.30
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/13/2026	14058	387716.51
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/15/2026	6349	168954.55
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/17/2026	416	11016.30
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	08/10/2026	2170	58785.30

144: Remarks and Signature

Remarks
Date of Notice	08/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	David Rodman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)